What lipid‑lowering therapy should be initiated for a 73‑year‑old woman with apolipoprotein B 1.21 g/L, triglycerides 2.33 mmol/L, HDL‑C 1.5 mmol/L, LDL‑C 4.05 mmol/L, normal renal function, HbA1c 5.5%, and blood pressure 125/73 mmHg?

Initiate High-Intensity Statin Therapy

This 73-year-old woman should be started on high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) with a target LDL-C <70 mg/dL (<1.8 mmol/L), given her markedly elevated LDL-C of 4.05 mmol/L (157 mg/dL) and apoB of 1.21 g/L, which indicates high atherogenic particle burden regardless of her lack of documented ASCVD. 1

Risk Assessment Framework

Her lipid profile reveals:

• LDL-C 4.05 mmol/L (157 mg/dL) – severely elevated
• ApoB 1.21 g/L – elevated (optimal <0.9 g/L, high-risk threshold >1.0 g/L)
• Triglycerides 2.33 mmol/L (206 mg/dL) – moderately elevated
• HDL-C 1.5 mmol/L (58 mg/dL) – protective level

This pattern represents hypertriglyceridemic hyperApoB phenotype, which carries substantially higher cardiovascular risk than LDL-C alone would suggest 2. The elevated apoB (1.21 g/L) directly measures atherogenic particle number and provides superior risk stratification compared to LDL-C, particularly in patients with metabolic abnormalities 3, 4.

Age Considerations

At 73 years, she falls into a critical decision zone. However, moderate-to-high intensity statin therapy reduces major vascular events even in patients >75 years without an upper age cutoff identified in clinical trials 1. The 2026 ACC/AHA guidelines emphasize that cardiovascular risk continues to increase with age, and elevated LDL-C and non-HDL-C remain predictive of events in those >75 years 5.

Treatment Algorithm

Step 1: Initiate High-Intensity Statin

Start atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily. High-intensity statins reduce LDL-C by ≥50% and have demonstrated 15% reduction in major vascular events compared to moderate-intensity therapy 1.

**Target: LDL-C <70 mg/dL (<1.8 mmol/L)** – this represents a >50% reduction from her baseline of 157 mg/dL.

Step 2: Reassess at 4-8 Weeks

Measure lipid panel including:

• LDL-C (primary target)
• ApoB (superior marker for residual risk) 3, 4
• Non-HDL-C (secondary target <100 mg/dL)
• Liver enzymes and CK if symptomatic

Step 3: Intensify if Needed

If LDL-C remains ≥70 mg/dL (≥1.8 mmol/L) on maximally tolerated statin:

Add ezetimibe 10 mg daily as first-line intensification 1. Ezetimibe is widely available as generic, has proven safety, and will achieve LDL-C <70 mg/dL in the majority of high-risk patients when added to statins 1.

Step 4: Consider PCSK9 Inhibitor (Rarely Needed in Primary Prevention)

Only if LDL-C remains ≥70 mg/dL despite maximal statin + ezetimibe AND cost/benefit ratio is favorable 1. This is uncommon in primary prevention.

Critical Nuances

ApoB vs. LDL-C Discordance: Her apoB of 1.21 g/L is disproportionately elevated relative to her LDL-C, indicating increased small dense LDL particles. When discordance exists, cardiovascular risk aligns better with apoB 3, 4. This supports aggressive LDL-lowering despite her being in "primary prevention."

Triglyceride Management: Her triglycerides of 2.33 mmol/L (206 mg/dL) will improve with statin therapy and lifestyle modification. If triglycerides remain ≥1.7 mmol/L after statin optimization, consider adding icosapent ethyl (if available) or fibrate, though statin remains the priority 6.

Shared Decision-Making: While guidelines emphasize shared decision-making in older adults 5, her markedly elevated atherogenic burden (apoB 1.21 g/L) and excellent functional status (normal BP, HbA1c, renal function) strongly favor treatment. The absolute benefit is greatest in those with highest baseline LDL-C 1.

Common Pitfalls to Avoid

• Don't use moderate-intensity statin initially – her LDL-C of 157 mg/dL requires ≥50% reduction, necessitating high-intensity therapy
• Don't delay treatment due to age alone – RCTs show benefit in patients >75 years 1
• Don't ignore apoB – it provides superior risk assessment and should guide therapy escalation 3, 4
• Don't add fibrate before optimizing statin + ezetimibe – statins remain first-line for LDL-C/apoB reduction
• Monitor for statin-associated muscle symptoms but recognize these are often transient and manageable with dose adjustment or alternate-day dosing 7

Monitoring Strategy

• 4-8 weeks: Lipid panel (LDL-C, apoB, non-HDL-C), liver enzymes
• 3-6 months: Repeat lipids if therapy adjusted
• Annually: Comprehensive lipid panel including apoB for long-term risk assessment 3